Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Cybin公司開始進行第3階段試驗，大力押注CYB003治療抑鬱症
Cybin Inc. (AMEX:CYBN) has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead candidate, CYB003, for treating Major Depressive Disorder (MDD) in a move that comes after three years of development.
Cybin Inc.（美國證券交易所股票代碼：CYBN）已經啓動了名爲ParadigM的第三階段關鍵計劃，該計劃旨在測試其主要候選藥物 CYB003 治療重度抑鬱症（MDD）的療效，此舉是在經過三年的開發之後採取的。
"Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone," said Doug Drysdale, CEO of Cybin.
Cybin首席執行官道格·德賴斯代爾表示：「在提交 CYB003 研究性新藥申請僅三年後，我們的第三階段計劃的啓動確實是一個重要而令人欣慰的里程碑。」
The design of the PARADIGM program, according to Drysdale, has been shaped by a collaborative process with the Food and Drug Administration (FDA), taking into account the challenges faced by other...
根據Drysdale的說法，ParadigM計劃的設計是由與美...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間